LY 3050258Alternative Names: LY-3050258
Latest Information Update: 19 Apr 2016
At a glance
- Originator Eli Lilly
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 22 Apr 2014 Eli Lilly plans a phase I trial for Healthy volunteers in USA (NCT02121834)
- 01 Dec 2013 Eli Lilly completes a phase I trial in Healthy volunteers in USA (NCT01929707)
- 21 Nov 2013 Eli Lilly completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01929707)